Cite

HARVARD Citation

    Higashiyama, T. et al. (2022). Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). European journal of cancer. pp. 210-218. [Online]. 
  
Back to record